Role of 18F-fluorodeoxyglucose positron emission tomography/computed tomography in predicting the pathologic response to preoperative chemoradiation therapy in patients with resectable T3 pancreatic cancer

World Journal of Surgery

Volumn 37, Issue 1, 2013, Pages 169-178

  Kittaka, Hirotada ^a   Takahashi, Hidenori ^a   Ohigashi, Hiroaki ^a   Gotoh, Kunihito ^a   Yamada, Terumasa ^a   Tomita, Yasuhiko ^a   Hasegawa, Yoshihisa ^b   Yano, Masahiko ^a   Ishikawa, Osamu ^a  

^a OSAKA MEDICAL CENTER FOR CANCER AND CARDIOVASCULAR DISEASES   (Japan)

^b Morinomiya Clinic   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

DIAGNOSTIC AGENT; FLUORODEOXYGLUCOSE F 18; RADIOPHARMACEUTICAL AGENT;

ADULT; AGED; ARTICLE; CANCER STAGING; CHEMORADIOTHERAPY; COMPUTER ASSISTED EMISSION TOMOGRAPHY; FEMALE; HUMAN; MALE; MIDDLE AGED; PANCREAS TUMOR; PATHOLOGY; PREOPERATIVE CARE; SCINTISCANNING; VERY ELDERLY;

ADULT; AGED; AGED, 80 AND OVER; CHEMORADIOTHERAPY; FEMALE; FLUORODEOXYGLUCOSE F18; HUMANS; MALE; MIDDLE AGED; NEOPLASM STAGING; PANCREATIC NEOPLASMS; POSITRON-EMISSION TOMOGRAPHY AND COMPUTED TOMOGRAPHY; PREOPERATIVE CARE; RADIOPHARMACEUTICALS;

EID: 84871924926     PISSN: 03642313     EISSN: 14322323     Source Type: Journal    
DOI: 10.1007/s00268-012-1775-x     Document Type: Article

References (43)

1. Cameron JL, Crist DW, Sitzmann JV et al (1991) Factors influencing survival after pancreaticoduodenectomy for pancreatic cancer. Am J Surg 161:120-124 discussion 124-125
2. Conlon KC, Klimstra DS, Brennan MF (1996) Long-term survival after curative resection for pancreatic ductal adenocarcinoma: clinicopathologic analysis of 5-year survivors. Ann Surg 223:273-279
3. Willett CG, Lewandrowski K, Warshaw AL et al (1993) Resection margins in carcinoma of the head of the pancreas: implications for radiation therapy. Ann Surg 217:144-148
4. Staley CA, Lee JE, Cleary KR et al (1996) Preoperative chemoradiation, pancreaticoduodenectomy, and intraoperative radiation therapy for adenocarcinoma of the pancreatic head. Am J Surg 171:118-124 discussion 124-115
5. Breslin TM, Hess KR, Harbison DB et al (2001) Neoadjuvant chemoradiotherapy for adenocarcinoma of the pancreas: treatment variables and survival duration. Ann Surg Oncol 8:123-132
6. Kamthan AG, Morris JC, Dalton J et al (1997) Combined modality therapy for stage II and stage III pancreatic carcinoma. J Clin Oncol 15:2920-2927
7. Mehta VK, Fisher G, Ford JA et al (2001) Preoperative chemoradiation for marginally resectable adenocarcinoma of the pancreas. J Gastrointest Surg 5:27-35
8. Pendurthi TK, Hoffman JP, Ross E et al (1998) Preoperative versus postoperative chemoradiation for patients with resected pancreatic adenocarcinoma. Am Surg 64:686-692
9. Snady H, Bruckner H, Cooperman A et al (2000) Survival advantage of combined chemoradiotherapy compared with resection as the initial treatment of patients with regional pancreatic carcinoma: an outcomes trial. Cancer 89:314-327
10. Talamonti MS, Small W Jr, Mulcahy MF et al (2006) A multi-institutional phase II trial of preoperative full-dose gemcitabine and concurrent radiation for patients with potentially resectable pancreatic carcinoma. Ann Surg Oncol 13:150-158
11. Chun YS, Cooper HS, Cohen SJ et al (2011) Significance of pathologic response to preoperative therapy in pancreatic cancer. Ann Surg Oncol 18:3601-3607
12. White RR, Xie HB, Gottfried MR et al (2005) Significance of histological response to preoperative chemoradiotherapy for pancreatic cancer. Ann Surg Oncol 12:214-221
13. Delbeke D, Martin WH (2001) Positron emission tomography imaging in oncology. Radiol Clin North Am 39:883-917
14. Hustinx R, Benard F, Alavi A (2002) Whole-body FDG-PET imaging in the management of patients with cancer. Semin Nucl Med 32:35-46
15. Kubota K (2001) From tumor biology to clinical PET: a review of positron emission tomography (PET) in oncology. Ann Nucl Med 15:471-486
16. 18F]-fluorodeoxyglucose positron emission tomography/computed tomography predicts early recurrence after pancreatic cancer resection. Int J Clin Oncol 16:39-44
17. Hopkins S, Fakih M, Yang GY (2010) Positron emission tomography as predictor of rectal cancer response during or following neoadjuvant chemoradiation. World J Gastrointest Oncol 2:213-217
18. 18F FDG PET: a systematic review. Radiology 254:707-717
19. 18F-fluorodeoxyglucose positron emission tomography to monitor clinical outcomes in patients treated with neoadjuvant chemo-radiotherapy for locally advanced pancreatic cancer. Am J Clin Oncol 33:257-261
20. Sobin L, Gospodarowicz M, Wittekind C (eds) (2010) TNM Classification of Malignant Tumors, 7th edn. Wiley-Blackwell, New York
21. Ohigashi H, Ishikawa O, Eguchi H et al (2009) Feasibility and efficacy of combination therapy with preoperative full-dose gemcitabine, concurrent three-dimensional conformal radiation, surgery, and postoperative liver perfusion chemotherapy for T3-pancreatic cancer. Ann Surg 250:88-95
22. Evans DB, Rich TA, Byrd DR et al (1992) Preoperative chemoradiation and pancreaticoduodenectomy for adenocarcinoma of the pancreas. Arch Surg 127:1335-1339
23. Eisenhauer EA, Therasse P, Bogaerts J et al (2009) New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). Eur J Cancer 45:228-247
24. Brucher BL, Weber W, Bauer M et al (2001) Neoadjuvant therapy of esophageal squamous cell carcinoma: response evaluation by positron emission tomography. Ann Surg 233:300-309
25. Flamen P, Van Cutsem E, Lerut A et al (2002) Positron emission tomography for assessment of the response to induction radiochemotherapy in locally advanced oesophageal cancer. Ann Oncol 13:361-368
26. Wieder HA, Brucher BL, Zimmermann F et al (2004) Time course of tumor metabolic activity during chemoradiotherapy of esophageal squamous cell carcinoma and response to treatment. J Clin Oncol 22:900-908
27. Van Heijl M, Omloo JM, van Berge Henegouwen MI et al (2011) Fluorodeoxyglucose positron emission tomography for evaluating early response during neoadjuvant chemoradiotherapy in patients with potentially curable esophageal cancer. Ann Surg 253:56-63
28. 18F-FDG PET is an early predictor of pathologic tumor response to preoperative radiochemotherapy in locally advanced rectal cancer. J Nucl Med 47:1241-1248
29. Capirci C, Rampin L, Erba PA et al (2007) Sequential FDG-PET/CT reliably predicts response of locally advanced rectal cancer to neo-adjuvant chemo-radiation therapy. Eur J Nucl Med Mol Imaging 34:1583-1593
30. 18Fluoro-deoxy-glucose positron emission tomography in assessing tumor response to preoperative chemoradiation therapy for locally advanced rectal cancer. J Surg Oncol 103:17-24
31. 18F] Fluorodeoxyglucose positron emission tomography predicts outcome for Ewing sarcoma family of tumors. J Clin Oncol 23:8828-8834
32. Evilevitch V, Weber WA, Tap WD et al (2008) Reduction of glucose metabolic activity is more accurate than change in size at predicting histopathologic response to neoadjuvant therapy in high-grade soft-tissue sarcomas. Clin Cancer Res 14:715-720
33. Benz MR, Czernin J, Tap WD, et al (2010) FDG-PET/CT imaging predicts histopathologic treatment responses after neoadjuvant therapy in adult primary bone sarcomas. Sarcoma 143540. Epub Apr 18
34. Cerfolio RJ, Bryant AS, Winokur TS et al (2004) Repeat FDG-PET after neoadjuvant therapy is a predictor of pathologic response in patients with non-small cell lung cancer. Ann Thorac Surg 78:1903-1909 discussion 1909
35. Shiraishi K, Nomori H, Ohba Y et al (2010) Repeat FDG-PET for predicting pathological tumor response and prognosis after neoadjuvant treatment in nonsmall cell lung cancer: comparison with computed tomography. Ann Thorac Cardiovasc Surg 16:394-400
36. 18Fluorodeoxyglucose PET is prognostic of progression-free and overall survival in locally advanced pancreas cancer treated with stereotactic radiotherapy. Int J Radiat Oncol Biol Phys 77:1420-1425
37. 18F- fluorodeoxyglucose positron emission tomography and the prognosis of patients with pancreatic adenocarcinoma. Cancer 79:695-699
38. 18F-fluorodeoxyglucose positron emission tomography for patients with pancreatic cancer. Int J Oncol 19:53-58
39. Heinrich S, Schafer M, Weber A et al (2008) Neoadjuvant chemotherapy generates a significant tumor response in resectable pancreatic cancer without increasing morbidity: results of a prospective phase II trial. Ann Surg 248:1014-1022
40. 18)F]-fluorodeoxy-d-glucose to predict the pathologic response of breast cancer to primary chemotherapy. J Clin Oncol 18:1676-1688
41. Katz MH, Fleming JB, Bhosale P, et al (2012) Response of borderline resectable pancreatic cancer to neoadjuvant therapy is not reflected by radiographic indicators. Cancer doi: 10.1002/cncr.27636. [Epub ahead of print]
42. Morgan DE, Waggoner CN, Canon CL et al (2010) Resectability of pancreatic adenocarcinoma in patients with locally advanced disease downstaged by preoperative therapy: a challenge for MDCT. AJR Am J Roentgenol 194:615-622
43. Takahashi H, Ohigashi H, Ishikawa O et al (2012) Perineural invasion and lymph node involvement as indicators of surgical outcome and pattern of recurrence in the setting of preoperative gemcitabine-based chemoradiation therapy for resectable pancreatic cancer. Ann Surg 255:95-102